📌 Update: We have turned bullish on a veterinary-diagnostics leader with a credible path to 15%+ upside over the next 12 months. Nearly 5,800 premium instrument placements and 11% installed-base growth supported 15% organic consumables growth. Quarterly EPS rose 18% to $4.01, prompting management to lift full-year guidance to $14.96–$15.16, implying 14%–16% growth. International recurring diagnostics revenue increased 14% organically. Our thesis rests on double-digit recurring revenue growth, instrument placements driving repeat consumables demand, and sustained mid-teens earnings expansion
🔷 Featured allocation: US$80,000 | Four years
At an assumed annual return of 12%, compounded annually, US$80,000 would grow to approximately US$125,881.55—a potential gain of US$45,881.55.
Explore Our Investment Plans
🔴 US$250,000+ | Five-year term
Target: 0.5% monthly income plus 15% annually.
At an assumed annual return of 15% PLUS 0.5% per month compounded annually, US$250,000 would grow to approximately US$678,254.86—a potential gain of US$427,254.86
🟡 US$100,000+ | Two-year term
Target: 0.5% monthly income plus 11% annually.
At an assumed annual return of 11% PLUS 0.5% per month compounded annually, US$100,000 would grow to approximately US$138,877.36—a potential gain of US$38,877.36
🟠 US$50,000 | Four-year term
Proposed annual return: 9%.
At an assumed annual return of 9% US$50,000 would grow to approximately US$70,579.08—a potential gain of US$38,877.36
🔵 $1M | 2 years – Targeted: 0.5% monthly income plus 21% annually.
At an assumed annual return of 21% PLUS 0.5% per month compounded annually, US$1M would grow to approximately US$1,516.706 —a potential gain of US$516,706
WhatsApp: bit.ly/Alpha-Binwani-Capital
Website: alphabinwanicapital.com
LinkedIn: bit.ly/Alpha-Binwani-Capital-LinkedIn
Newsletter: bit.ly/FreeAlphaNewsletter
#VeterinaryDiagnostics #AnimalHealth #HealthcareStocks #EquityResearch #InvestmentOutlook #StockMarket #GrowthInvesting
